Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2011-08-30
2011-08-30
Reddig, Peter J (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S006120, C435S007100, C435S007210, C435S007230
Reexamination Certificate
active
08007995
ABSTRACT:
The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
REFERENCES:
patent: 4275149 (1981-06-01), Litman et al.
patent: 4318980 (1982-03-01), Boguslaski et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4737456 (1988-04-01), Weng et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 5242828 (1993-09-01), Bergstrom et al.
patent: 5382510 (1995-01-01), Levine et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5667171 (1997-09-01), Fowell et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5952170 (1999-09-01), Stroun et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6225047 (2001-05-01), Hutchens et al.
patent: 6329209 (2001-12-01), Wagner et al.
patent: 6399063 (2002-06-01), Hudziak et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6767541 (2004-07-01), Slamon et al.
patent: 2003/0153013 (2003-08-01), Huang
patent: 2004/0038428 (2004-02-01), MacBeath et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: WO 98/24893 (1998-06-01), None
patent: WO 99/51773 (1999-10-01), None
patent: WO 00/56934 (2000-09-01), None
patent: WO 2004/020583 (2004-03-01), None
Taber's Cyclopedic Medical Dictionary (1985, F.A. Davis Company, Philadelphia, p. 274).
Busken, C et al. (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Kaiser (Science, 2006, 313: 1370).
Krontiris and Capizzi (Internal Medicine, 4th Edition, Editor-in-chief Jay Stein, Elsevier Science, 1994 Chapters 71-72, pp. 699-729).
Carter, S. K. et al. (Chemotherapy of Cancer; Second edition; John Wiley & Sons: New York, 1981; appendix C.
U.S. Appl. No. 10/395,503, filed Mar. 24, 2003.
U.S. Appl. No. 11/401,502, filed Apr. 11, 2006.
Aghmesheh et al., Gynecol Oncol. Apr. 2005; 97(1):16-25.
Altschul et al.; 1996, Methods in Enzymology 266:460-480.
Ausubul et al. eds., 1995, Current Protocols in Molecular Biology, Units 2 [Northern Blotting], 4 [Southern Blotting], 15 [Immunoblotting] and 18 [PCR Analysis].
Bao, J. Chromatogyr. B. Biomed. Sci. 699:463-80 (1997).
Bartek et al., Int J. Cancer (1985) 36:299-306.
Bradley, in Robertson, ed., 1987, Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, (IRL, Oxford), pp. 113-152.
Bromann PA, et al., Oncogene. Oct. 18, 2004; 23(48):7957-68.
Brooks et al., Cancer Epidemiol. Biomarkers Prev., 1998, 7:531-536.
Carter et al., 1993, Proc. Natl. Acad. Sci. USA 89:4285.
Carter, et al., 1986, Nucl. Acids Res. 13:4331.
Chang et al., Breast Cancer Res Treat. Sep. 2001; 69(2):101-13.
Chothia, 1976, J. Mol. Biol., 150:1.
Clark E, et al., Proceedings of the Am Soc Clin Oncol Abstract 3010, 2005.
Clark, M., ed., 1993, Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, Nottingham Academic, pp. 45-64.
Cohen, Jack, 1988, Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC Press.
Couture, L.A. and Stinchcomb, D.T.; 1996, Tends Genet. 12:510-515.
Creighton, The Proteins, (W.H. Freeman & Co., N.Y.), 1996 p. v-x.
De Marzo et al., Am. J.Patol. 155(6):1985-1992 (1999).
Donnelly et al., 1997, Ann. Rev. Immunol. 15:617-648.
Fiucci et al, Oncogene, 2002, 4:21(15) 2365-2375.
Fossati R, et al., J. Clin. Oncol Oct. 1998; 16(10:3439-60.
Foulkes et al., Cancer Res. Feb. 1, 2004: 64(3):830-5.
Gamallo et al., Mod. Pathol. 2001, 14(7):650-4.
Gipponni et al., J. Surg. Oncol. Mar. 1, 2004; 85(3):102-111.
Hanahan D., et al., Cell. Jan. 7, 2000; 100(1):57-70.
Harlow and Lane, Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory: New York, 1988).
Irby RB et al., Oncogene. Nov. 20, 2000; 19(49):5636-42.
Ishizawar R et al., Cancer Cell. Sep. 2004; 6(3):209-14.
Iyer, R.P., et al.; J. Am. Chem. Soc. 112:1253-1254.
Iyer, R.P., et al.; J. Org. Chem. 55:4693-4698.
Jakobovits, 1998, Exp. Opin. Invest. Drugs 7(4):607-614.
Jemal A. et al., 2002, CA Cancer J. Clin. Jan.-Feb. 2002, 52 (1):23-47.
Jensen OM, et al, Eur. J. Cancer. 1990; 26(11-12):1167-256.
Johnson F.M., et al., Dasatinib Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells; Clinical Cancer Research, The American Association for Cancer Research, US, Oct. 1, 2005; vol. 11 No. 19 I, pp. 6924-6932.
Jones et al., 1986, Nature 321:522-525.
Joo, H.J. et al., Increases Expression of Caveolin-1 and Microvessel Density Correlates with Metastasis and Poor Prognosis in Clear Cell Renal Carcinoma; BJU international, vol. 93, 2004, pp. 291-296, XP002439942.
Kobayashi et al., Clinical Cancer Research, 10, 572-580, 2004.
Korsching et al., J. Pathol. Aug. 2005; 206(4):451-7.
Kovacs et al., J Clin Pathol Feb. 2003; 56(2):139-41.
Kozak, 1989, Mol. Cell Biol., 9:5073-5080.
Laakso M., et alk.; Clin Cancer Res. Jul. 15, 2006; 12(14 Pt 1):4185-91.
Leong et al., Appl. Immunohistochem. 4(3):201 (1996).
Lethe et al., Int. J. Cancer 76(6):903-908 (1998).
Li et al., 1992, Cell 69:915.
Lombardo L.J. et al., Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl-piperazin-1-yl-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, a Dual Scr/Able kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays; Journal of Medical Chemistry, American Chemical Society, Washington, DC, Dec. 7, 2004, vol. 47(27):6658-61.
Manual of Histological Staining Method of the Armed Forces Institute of Pathology, 3rd edition (196) Lee G. Luna, HT (ASCP) Editor, The Blakston Division McGraw-Hill Book Company, NewYork.
Marrogi et al., 1999, J. Cutan, Pathol. 26(8):369-378.
Muller et al., 1991, MCB 11:1785.
Nam, Sangkil et al., Action of the Src Family Kinase Inhibito, Dasatinib (BMS-354825), on Human Prostate Cancer Cells; Cancer Research, American Association for Cancer Research, Baltimore, Maryland US, vol. 65, No. 20, pp. 9185-9189, Oct. 15, 2005.
National Cancer Institute of Canada: Canadian Cancer Statistics 1996, Toronto, Canada 1996; 21-23.
Nishizuka, S. et al., Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, Tissue Array Profiling, Cancer Research, vol. 63, Sep. 1, 2003, pp. 5243-5250, XP002439941.
O'Sullivan et al., Methods for the Preparation of Enzyme-Antibody conjugates for use in Enzyme Immunoassay, in Methods in Enzym, (ed. J. Langone & H. Van Vunakis), Academic press, New York, 73:147-166 (1981).
Paredes et al., Pathol. Res. Pract. 2002; 198(12):795-801.
Parra et al., J. Vasc. Surg. 28:669-675 (1998).
Partridge et al., 1996, Antisense & Nucleic Acid Drug Development 6:169-175.
Peralta et al., Cancer Oct. 1, 1999; 86(7):12630-72.
Perou CM, et al.; Nature, Aug. 17, 2000; 406(6796):747-52.
Playford MP et al., Oncogen. Oct. 18, 2004; 23(48):7928-46.
Protein Microarrays (2004) Mark Schena (Ed) Jones & Bartlett Publishers, Inc.
Reis-Filbo JS, J. Pathol. Nov. 2005; 207(3):367-369.
Riechmann et al., 1988, Nature 332:323-327.
Rongen et al., J. Immunol. Methods 204:105-133 (1997).
Sambrook et al.; 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., New York: Cold Spring Harbor Press.
Schmalzing and Mashabeh, Electrophoresis 18:2184-93 (1997).
Self and Cook, Curr. Opin. Biotechnol. 7:60-65 (1996).
Shupnik MA et al., Oncogene. Oct. 18, 2004; 23(48):7979-89.
Sims et al., 1993, J. Immunol. 151:2296.
Slamon DJ, et al., N Engl J. Med. Mar. 15, 2001; 344(11):783-92.
Song I, et al., Cancer Res 66(11):5542-8, 2006.
Sorlie T et al., Proc Natl Acad Sci USA, Sep. 11, 2001; 98:10869-74.
Sotiriou C., et al., Proc Natl Acad Sci USA—Sep. 2, 2003; 100(18):10393-8.
Srinivasan D, et al., Cancer Res Jun. 1, 2006; 66(11):5648-55.
Strizzi et al., J Cell Physiol. Nov. 2004; 201(2):266-76.
Sudol M., Oncogen. Aug. 1994; 9(8):2145-52.
Synthesis 1:1-5 (1988), Negishi, E. et al.
The Armed Forces Institute of Pathology Advanced Laboratory Methods in Histology and Path
Clark Edwin A.
Dering Judy
Finn Richard S.
Ginther Charles L.
Slamon Dennis J.
Bristol--Myers Squibb Company
Reddig Peter J
The Regents of the University of California
Woodcock & Washburn LLP
LandOfFree
Moesin, caveolin 1 and yes associated protein 1 as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Moesin, caveolin 1 and yes associated protein 1 as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Moesin, caveolin 1 and yes associated protein 1 as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2710597